dc.contributor.author | Etemadi, J | |
dc.contributor.author | Majidi, T | |
dc.contributor.author | Motavalli, R | |
dc.contributor.author | Bonyadi, M | |
dc.contributor.author | Vahed, SZ | |
dc.contributor.author | Zaker, B | |
dc.contributor.author | Ardalan, M | |
dc.date.accessioned | 2018-08-26T09:01:15Z | |
dc.date.available | 2018-08-26T09:01:15Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54988 | |
dc.description.abstract | Background: Familial Mediterranean Fever (FMF) is the most common inherited autoinflammatory disease. Kidney involvement in FMF is usually attributed to secondary amyloidosis. Non-amyloid glomerular involvement has also been reported. Objectives: We suppose that heterozygous mutation of Mediterranean fever (MEFV) gene could be the underlying cause in some cases of mesangial proliferative glomerulonephritis (MePGN) in FMF endemic area. Materials and Methods: This prospective study was done between 2013 and 2015 in North- West of Iran among the Azari-Turkish population. A panel of MEFV gene including M680I, R761H, M694V, R408Q, E148Q, A744S, F479L, P369S, V726A, M694I, and E167D were studied in a group of patients with idiopathic MePGN. Clinical characteristics and therapeutic responses were compared between those with and without a mutation. A total of 39 idiopathic MePGN patients and 156 healthy subjects were studied. Results: Heterozygote mutations of MEFV gene were detected in 11/39 (28.2%) of MePGN patients and 46/156 (17.3%) of controls. Clinical response regarding 24 hours urine protein excretion was significant in mutation-negative patients after 6 months of follow-up. Conclusions: This study shows a possible underlying role of heterozygous MEFV gene mutation in the clinical course of some case of idiopathic MePGN, particularly in FMF endemic population. é 2018 The Author(s). | |
dc.language.iso | English | |
dc.relation.ispartof | Journal of Nephropathology | |
dc.subject | angiotensin receptor antagonist | |
dc.subject | corticosteroid | |
dc.subject | cyclosporine | |
dc.subject | dipeptidyl carboxypeptidase inhibitor | |
dc.subject | acute kidney failure | |
dc.subject | adult | |
dc.subject | aged | |
dc.subject | analysis of variance | |
dc.subject | Article | |
dc.subject | cohort analysis | |
dc.subject | controlled study | |
dc.subject | deep vein thrombosis | |
dc.subject | diabetes mellitus | |
dc.subject | drug dose reduction | |
dc.subject | edema | |
dc.subject | endemic disease | |
dc.subject | evaluation and follow up | |
dc.subject | familial Mediterranean fever | |
dc.subject | female | |
dc.subject | gene | |
dc.subject | gene mutation | |
dc.subject | genotype phenotype correlation | |
dc.subject | hepatitis | |
dc.subject | heterozygote | |
dc.subject | human | |
dc.subject | immunofluorescence test | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | MEFV gene | |
dc.subject | middle aged | |
dc.subject | polymerase chain reaction | |
dc.subject | proliferative glomerulonephritis | |
dc.subject | prospective study | |
dc.subject | protein urine level | |
dc.subject | proteinuria | |
dc.subject | qualitative analysis | |
dc.subject | reproducibility | |
dc.subject | restriction fragment length polymorphism | |
dc.subject | retrospective study | |
dc.subject | urinalysis | |
dc.subject | young adult | |
dc.title | Mediterranean fever gene mutations in patients with idiopathic mesangial proliferative glomerulonephritis | |
dc.type | Article | |
dc.citation.volume | 7 | |
dc.citation.issue | 2 | |
dc.citation.spage | 45 | |
dc.citation.epage | 50 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.15171/jnp.2018.13 | |